Literature DB >> 14638905

Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors.

Bishoy Rizkalla1, Josephine M Forbes, Mark E Cooper, Zemin Cao.   

Abstract

A link between angiotensin II and cell proliferation has previously been reported. However, there remains controversy as to the role of the individual angiotensin II receptor subtypes in mediating these effects and their link to angiogenic cytokines and their receptors. Male Sprague-Dawley rats were infused with either angiotensin II or vehicle for 14 d at a dose of 58.3 ng/min. Angiotensin II-infused rats received no treatment, an AT(1) receptor antagonist valsartan (30 mg/kg per d), or an AT(2) receptor antagonist PD123319 (830 ng/min). Gene expression of vascular endothelial growth factor (VEGF) and receptor VEGF-R2, as well as Tie-2 and its ligands angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) were assessed by reverse transcription-PCR. Protein expression was assessed by Western blotting and immunohistochemistry. Gene and protein expression of VEGF, Ang-1, and Ang-2 were increased by angiotensin II infusion. Valsartan and PD123319 attenuated angiotensin II-associated increases in VEGF gene and protein expression. Ang-1 and Ang-2 gene but not protein expression were reduced by both treatments. These changes occurred in the context of attenuation of angiotensin II-induced glomerular cell proliferation by both valsartan and PD123319. In situ hybridization and immunohistochemical studies localized VEGF, Ang-1, and Ang-2 expression to the epithelial cells of the glomerulus, and VEGF-R2 and Tie-2 receptors to the endothelial cells of the kidney. These findings extend the increasing evidence that the AT(2) receptor, in addition to the AT(1) receptor subtype, plays an important role in mediating the proliferative actions of angiotensin II in the kidney.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638905     DOI: 10.1097/01.asn.0000099374.58607.c9

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  27 in total

Review 1.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

2.  Corticosteroid-regulated genes in rat kidney: mining time series array data.

Authors:  Richard R Almon; William Lai; Debra C DuBois; William J Jusko
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-06-28       Impact factor: 4.310

Review 3.  Angiogenesis and autosomal dominant polycystic kidney disease.

Authors:  Jennifer L Huang; Adrian S Woolf; David A Long
Journal:  Pediatr Nephrol       Date:  2012-09-19       Impact factor: 3.714

4.  Angiotensin II promotes development of the renal microcirculation through AT1 receptors.

Authors:  Kirsten Madsen; Niels Marcussen; Michael Pedersen; Gitte Kjaersgaard; Carie Facemire; Thomas M Coffman; Boye L Jensen
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

Review 5.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

6.  Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells.

Authors:  Denis Feliers; Balakuntalam S Kasinath
Journal:  Mol Cell Endocrinol       Date:  2009-09-16       Impact factor: 4.102

Review 7.  Pathogenesis and treatment of peritoneal membrane failure.

Authors:  Ramesh Saxena
Journal:  Pediatr Nephrol       Date:  2007-09-21       Impact factor: 3.714

8.  Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats.

Authors:  Zhong-Sheng Zhu; Jin-Ming Wang; Shao-Liang Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 9.  Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.

Authors:  Niels H Andersen; Carl E Mogensen
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

10.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.

Authors:  Stefan Wilop; Sabine von Hobe; Martina Crysandt; Albert Esser; Rainhardt Osieka; Edgar Jost
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.